Management of Oropharynx Cancer and Associated Toxicities
This course will describe the presentation, evaluation, and management of patients with oropharyngeal cancers, especially with regard to the importance of multidisciplinary management of patients with HPV-related cancers. The optimal evaluation of a patient at diagnosis and the importance of HPV-status in counseling will be reviewed; the role of radiation, chemotherapy, and surgery will also be discussed. Radiation techniques, such as IMRT, IGRT, and proton therapy, will be reviewed comprehensively, including details of contouring and integrating chemotherapy and surgery. The last portion of the course will discuss details of managing the need for target delineation and normal tissue protection, with review of the organs at risk and data on optimal normal tissue.
This program is designed to meet the interest of radiation oncologists, medical oncologists, surgeons and residents in training.
- Explain the issues related to HPV-related oropharyngeal cancer and provide appropriate patient evaluation and counseling.
- Explain the issues and details involved in appropriate radiation-based treatment, including the use of IMRT, IGRT, and proton therapy.
- Implement normal structure dose constraints and counsel patients regarding side effects and possible complications of radiation-based therapy of oropharynx cancer.
The following people served as the developers of this activity and their disclosures are listed below.
- Beth M. Beadle, MD, PhD receives compensation or funding from NIH.
- G. Brandon Gunn, MD holds a leadership position at MD Anderson Cancer Center.
- Dr. Avraham Eisbruch, MD receives compensation or funding and holds a leadership position at NIH.
Additionally, the Education and CME/MOC Committees had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.50 Certificate of AttendanceThis activity was designated for 1.50 AMA PRA Category 1 Credit™.
- 1.50 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this Enduring material for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.50 self-assessment credits.
ASTRO members must log in to the ASTRO website to view and receive the discounted member rate.
- Nonmember: $105
- Member: $55
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website for that 3 year period regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.